Analysts Offer Predictions for AMLX Q1 Earnings

Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) – HC Wainwright issued their Q1 2025 EPS estimates for Amylyx Pharmaceuticals in a research report issued on Wednesday, March 5th. HC Wainwright analyst A. Fein anticipates that the company will post earnings of ($0.43) per share for the quarter. HC Wainwright has a “Buy” rating and a $12.00 price target on the stock. The consensus estimate for Amylyx Pharmaceuticals’ current full-year earnings is ($2.20) per share. HC Wainwright also issued estimates for Amylyx Pharmaceuticals’ Q2 2025 earnings at ($0.43) EPS, Q3 2025 earnings at ($0.43) EPS, Q4 2025 earnings at ($0.43) EPS and FY2029 earnings at $0.07 EPS.

A number of other brokerages have also weighed in on AMLX. Robert W. Baird raised shares of Amylyx Pharmaceuticals from a “neutral” rating to an “outperform” rating and lifted their price target for the company from $3.00 to $11.00 in a research note on Monday, November 18th. Baird R W raised Amylyx Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Monday, November 18th. Five investment analysts have rated the stock with a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $7.33.

Amylyx Pharmaceuticals Price Performance

NASDAQ AMLX opened at $3.61 on Friday. The stock’s 50-day moving average is $3.53 and its 200-day moving average is $3.85. Amylyx Pharmaceuticals has a one year low of $1.58 and a one year high of $19.18. The firm has a market cap of $247.46 million, a P/E ratio of -0.95 and a beta of -0.51.

Amylyx Pharmaceuticals (NASDAQ:AMLX) last issued its quarterly earnings data on Tuesday, March 4th. The company reported ($0.55) EPS for the quarter, missing the consensus estimate of ($0.49) by ($0.06). The company had revenue of ($0.67) million during the quarter.

Insider Activity at Amylyx Pharmaceuticals

In other news, CEO Justin B. Klee sold 7,471 shares of the company’s stock in a transaction dated Monday, January 6th. The shares were sold at an average price of $4.04, for a total value of $30,182.84. Following the sale, the chief executive officer now directly owns 3,176,788 shares of the company’s stock, valued at approximately $12,834,223.52. This represents a 0.23 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Joshua B. Cohen sold 11,851 shares of the business’s stock in a transaction that occurred on Monday, February 3rd. The stock was sold at an average price of $3.47, for a total value of $41,122.97. Following the transaction, the chief executive officer now directly owns 3,201,247 shares in the company, valued at approximately $11,108,327.09. This trade represents a 0.37 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 27,169 shares of company stock valued at $97,274. 11.70% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the business. Bank of America Corp DE increased its holdings in shares of Amylyx Pharmaceuticals by 165.9% in the fourth quarter. Bank of America Corp DE now owns 2,426,263 shares of the company’s stock valued at $9,171,000 after purchasing an additional 1,513,748 shares during the last quarter. Almitas Capital LLC lifted its position in Amylyx Pharmaceuticals by 2.2% during the fourth quarter. Almitas Capital LLC now owns 2,032,370 shares of the company’s stock worth $7,682,000 after acquiring an additional 43,807 shares during the last quarter. Boxer Capital Management LLC bought a new stake in shares of Amylyx Pharmaceuticals during the fourth quarter worth approximately $6,615,000. Nantahala Capital Management LLC increased its stake in shares of Amylyx Pharmaceuticals by 3.4% during the fourth quarter. Nantahala Capital Management LLC now owns 1,452,153 shares of the company’s stock worth $5,489,000 after purchasing an additional 47,589 shares during the period. Finally, Connor Clark & Lunn Investment Management Ltd. boosted its stake in Amylyx Pharmaceuticals by 43.4% in the 4th quarter. Connor Clark & Lunn Investment Management Ltd. now owns 1,263,353 shares of the company’s stock valued at $4,775,000 after purchasing an additional 382,608 shares during the period. 95.84% of the stock is owned by institutional investors and hedge funds.

About Amylyx Pharmaceuticals

Amylyx Pharmaceuticals, Inc, a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada.